Genomic Health, Inc. has announced the results of a multi-center Japanese study demonstrating that the Oncotype DX breast cancer assay had significant prognostic value in Japanese women with estrogen receptor-positive early-stage breast cancer. Oncotype DX identified a large portion of patients in Japan who had estrogen receptor-positive early-stage breast cancer as having a low likelihood of distant recurrence. Researchers from the Japan Breast Cancer Research Group presented results in an oral presentation at the 2009 Kyoto Breast Cancer Consensus Conference International Convention in Kyoto, Japan. Oncotype DX has been available in Japan since 2007 via SRL, Inc., the exclusive distributor of Oncotype DX in Japan. "These results highlight the clinical utility of this assay for treatment planning for early-stage breast cancer across populations, including patients in Japan with breast cancer," said Masakazu Toi, M.D., Ph.D., Professor of the Department of Surgery at Kyoto University School of Medicine and a director of the Japan Breast Cancer Research Group. "Based on these results, we believe that Oncotype DX should be integrated into standard breast cancer treatment planning for patients in Japan." Researchers evaluated tumor samples from 200 patients with early-stage, estrogen receptor-positive, lymph node negative breast cancer, who were treated with tamoxifen, and who had surgery between 1992 and 1998. The Oncotype DX breast cancer assay was performed on all individual tumor specimens and the continuous Recurrence Score was strongly associated with the risk of distant recurrence (p